Pharmaceuticals major AstraZeneca is investing in a US$4 million health research project covering metabolic and cardiovascular diseases, to be carried out by Brazilian universities over the next five years.
For the first three year phase of the project, bids are invited by 26th June latest for the initial US$ 2.4 million in aid which will be provided jointly by AstraZeneca (via its MedImmune subsidiary) and by the São Paulo Research Foundation (FAPESP). Successful bid will be announced October 7th.
The focus of the research – to be carried out in conjunction with universities in the state of São Paulo – is for the development scientific and technical solutions to human health problems caused by obesity and/or diabetes. These in turn can be responsible for chronic kidney disease, post-surgical illnesses and resistance to insulin treatment. Potential solutions include appetite suppression.
|“Cardiovasular and metabolic disease is a main therapy area for MedImmune, and we are pleased to enter this exciting new research agreement with FAPESP to find and access some of the most innovative science in the São Paulo area, a region ripe in metabolic expertise and innovation,” said Cristina Rondinone, Vice President and Head of MedImmune’s Cardiovascular and Metabolic Disease (CVMD) Innovative Medicines Unit. “Partnering with academia to identify and qualify new targets and underlying biology is critical in translating discoveries to create innovative new medicines in areas of high unmet medical need.”|
|The call for proposals followed the signing of a technical accord between AstraZeneca and FAPESP, which provides for US$2 million investment by either party. It also reveals a growing interest in Brazil’s scientific sector from AstraZeneca, which has been supporting the Science without Borders student mobility programme. You can read more about the MedImmune initiative by clicking here.|